Improved Drug Delivery to Brain Metastases by Peptide-Mediated Permeabilization of the Blood-Brain Barrier.
Animals
Blood-Brain Barrier
/ chemistry
Brain Neoplasms
/ drug therapy
Cell Line, Tumor
Dogs
Dose-Response Relationship, Drug
Endocytosis
Humans
Imidazoles
/ administration & dosage
Madin Darby Canine Kidney Cells
Melanoma
/ drug therapy
Mice
Mutation
Oximes
/ administration & dosage
Peptides
/ administration & dosage
Proto-Oncogene Proteins B-raf
/ genetics
Rats
Xenograft Model Antitumor Assays
Journal
Molecular cancer therapeutics
ISSN: 1538-8514
Titre abrégé: Mol Cancer Ther
Pays: United States
ID NLM: 101132535
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
14
02
2019
revised:
06
06
2019
accepted:
19
08
2019
pubmed:
31
8
2019
medline:
2
6
2020
entrez:
31
8
2019
Statut:
ppublish
Résumé
Patients with melanoma have a high risk of developing brain metastasis, which is associated with a dismal prognosis. During early stages of metastasis development, the blood-brain barrier (BBB) is likely intact, which inhibits sufficient drug delivery into the metastatic lesions. We investigated the ability of the peptide, K16ApoE, to permeabilize the BBB for improved treatment with targeted therapies preclinically. Dynamic contrast enhanced MRI (DCE-MRI) was carried out on NOD/SCID mice to study the therapeutic window of peptide-mediated BBB permeabilization. Further, both
Identifiants
pubmed: 31467182
pii: 1535-7163.MCT-19-0160
doi: 10.1158/1535-7163.MCT-19-0160
doi:
Substances chimiques
Imidazoles
0
Oximes
0
Peptides
0
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
dabrafenib
QGP4HA4G1B
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2171-2181Informations de copyright
©2019 American Association for Cancer Research.